No drug/drug interaction studies have been conducted for Bravelle™ in humans.
Aside from possible ovarian hyperstimulation (see WARNINGS) and multiple gestations (see WARNINGS), little is known concerning the consequences of acute overdosage with Bravelle™.
Bravelle™ is contraindicated in women who have:
A high FSH level indicating primary ovarian failure.
Uncontrolled thyroid and adrenal dysfunction.
An organic intracranial lesion such as pituitary tumor.
The presence of any cause of infertility other than anovulation.
Abnormal bleeding of undetermined origin.
Ovarian cysts or enlargement not due to polycystic ovary syndrome.
Prior hypersensitivity to urofollitropins, purified.
Bravelle™ is contraindicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of Bravelle™ when administered during pregnancy.